Apellis: No indication roduct, manufacturing issues spur retinal vasculitis

 

• Confirmed seven total events of non-occlusive/occlusive retinal vasculitis since launch; more than 68,000 SYFOVRE vials distributed to date
  

• Zero events were reported in clinical trials, following more than 23,000 clinical trial injections to date
  

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on its review of rare events of retinal vasculitis reported in real-world treatment with SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

https://finance.yahoo.com/news/apellis-provides-review-rare-safety-185200379.html